SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop ...

Hang Zhou, PhD, senior vice president and head of bioprocess research and development , WuXi Biologics. [WuXi Biologics] Raman spectroscopy has become a first-choice PAT for monitoring and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

BGI, Complete Genomics, MGI, WuXi AppTec, and WuXi Biologics are obvious targets for The BIOSECURE Act. It is well known that WuXi entities have become dangerously entwined with American biotech.